Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation

Clicks: 252
ID: 6834
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #142 of 242 articles by views in research reports in clinical cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 242 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation Joachim R Ehrlich1, Matthias Hammwöhner3, Andreas Goette2,31Deutsche Klinik für Diagnostik, Department of Cardiology, Wiesbaden, 2Working Group, Molecular Electrophysiology, University Hospital Magdeburg, 3Department of Cardiology and Intensive Care Medicine, St Vincenz-Hospital Paderborn, GermanyAbstract: Atrial fibrillation is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are constantly rising with advancing population age. A severe complication of untreated atrial fibrillation is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, atrial fibrillation is a major contributor to thromboembolic events, especially in the older population. Depending on the CHADS2 risk score for thromboembolic events, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism, including apoplectic strokes. However, due to the drawbacks of current anticoagulation therapy, new substances for oral anticoagulation therapy are currently being evaluated in various clinical studies. This article will provide an up to date overview of orally active compounds for the future treatment of atrial fibrillation using the direct thrombin inhibitor, dabigatran.Keywords: atrial fibrillation, anticoagulation, pathophysiology, pharmacology, stroke
Reference Key
joachim2012dabigatranresearch Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Joachim R Ehrlich;Matthias Hammwöhner;Andreas Goette and
Journal research reports in clinical cardiology
Year 2012
DOI
10.2147/RRCC.S17430
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.